Todd Chaney

Aspen Neuroscience announces appointment of Damien McDevitt, PhD as President and Chief Executive Officer

by

SAN DIEGO, January 25, 2021 — Aspen Neuroscience, a private biotechnology company developing the first autologous neuron replacement therapy to treat Parkinson’s disease, announced today that it has appointed biotech leader Damien McDevitt, PhD, as President and Chief Executive Officer. Dr. McDevitt will also be joining the company’s board of directors.  “We are excited to … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

An Autologous Stem Cell-Based Therapy for Parkinson’s Disease

by

Cell therapies hold great promise to treat Parkinson’s disease, but there’s an ongoing debate over how to best do this. One group—and I am firmly in this camp—maintains an autologous therapy, derived from a patient’s own cells, is the correct path. Others believe an allogeneic approach, using donor cells, would be more cost-effective.

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience to Present at 2020 Virtual Cell & Gene Meeting on the Mesa

by

SAN DIEGO, October 5, 2020 — Aspen Neuroscience announced today that Howard Federoff, MD, PhD, Chief Executive Officer, will present at the annual Cell & Gene Meeting on the Mesa to be held virtually October 12-16, 2020. Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is a five-day … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience announces management transition

by

SAN DIEGO, Aug. 3, 2020 /PRNewswire/ – Aspen Neuroscience, a private biotechnology company developing the first autologous neuron replacement therapy to treat Parkinson’s disease, today announced that Dr. Jeanne Loring, co-founder and Chief Scientific Officer, will transition to the role of Special Advisor to the Company’s Research and Development Committee. Dr. Loring is Professor emeritus … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Gets $70 Million Series A Funding Round

by

Aspen Neuroscience, a private biotech company developing the first autologous neuron replacement therapy to treat Parkinson’s disease, announced the close of its Series A funding round of $70 million. OrbiMed led the investment round with participation from ARCH Venture Partners, Frazier Healthcare Partners, Domain Associates, Section 32, and entrepreneur Sam Altman.

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

$70 Million Raised for Neuron Replacement Therapy Techniques to Treat Parkinson’s

by

Aspen Neuroscience has raised $70 million to advance the development of Parkinson’s disease therapies using patients’ own cells. The products, ANPD001 and ANPD002, are the first-ever Parkinson’s treatments designed to use a patient’s own cells as a replacement to restore neuronal function and to modify disease progression. This approach is referred to as an autologous … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Announces Reconstitution of the Board of Directors with the Addition of Seasoned Industry Executives

by
building APC 0096 hdr

SAN DIEGO, April 6, 2020 — Aspen Neuroscience, a private biotechnology company developing the first autologous neuron replacement therapy to treat Parkinson disease, today announced the reconstitution of its Board of Directors, including a new Board Chair, following the closing of its Series A financing of $70 million.

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Announces $70 Million Series A Financing Led by OrbiMed to Advance Development of the First Autologous Neuron Replacement Therapy to Treat Parkinson Disease

by

SAN DIEGO, Apr. 1, 2020 /PRNewswire/ — Aspen Neuroscience, a private biotechnology company developing the first autologous neuron replacement therapy to treat Parkinson’s disease, today announced the close of its Series A funding round of $70 million. OrbiMed led the investment round with participation from ARCH Venture Partners, Frazier Healthcare Partners, Domain Associates, Section 32, and Sam Altman.

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience announces board of directors and scientific advisory board

by

SAN DIEGO, Jan. 9, 2020 /PRNewswire/ — Aspen Neuroscience, Inc., a private biotechnology company developing the first autologous neuron replacement therapy to treat Parkinson disease, has announced the members of its Board of Directors and Scientific Advisory Board. These boards bring together many of the world’s most distinguished industry and academic minds to deliver Aspen’s personalized cell therapy to persons suffering with Parkinson disease.

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Possible Parkinson’s Stem Cell Treatment in San Diego, $6.5 Million and Loads of Media Coverage

by

A San Diego firm that has $22 million worth of financial roots in the California stem cell agency this month snagged a bonus — a ton of favorable attention for its efforts to treat Parkinson’s disease.  The fledgling business is Aspen Neuroscience, Inc., which was co-founded by Jeanne Loring, professor emeritus at the Scripps Research … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Logo

Aspen Neuroscience leverages stem cell biology and genomics to provide the world’s first autologous induced pluripotent stem cell (iPSC)-derived neuron replacement therapy for Parkinson's disease.

Contact

10835 Road to the Cure
Ste. 100
San Diego, CA 92121

© 2025 Aspen Neuroscience - All Rights Reserved